Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionRestricted Stock Units · Derivative | 3,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001866 · doc4.xml · derivative · entry 10 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,346 Underlying: Common Stock · 3,172 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Tax withholdingCommon Stock | 1,534 | $106.11 | $162,772.74 |
DisclosureSEC source: 0001225208-25-001866 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,401 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
Exercise / conversionCommon Stock | 3,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001866 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionRestricted Stock Units · Derivative | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · derivative · entry 9 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,702 Underlying: Common Stock · 1,850 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Tax withholdingCommon Stock | 895 | $106.11 | $94,968.45 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,206 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
Exercise / conversionCommon Stock | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · derivative · entry 9 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,725 Underlying: Common Stock · 4,362 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC |
Brennan Daniel J.EVP and CFO
|
Tax withholdingCommon Stock | 2,110 | $106.11 | $223,892.10 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 245,590 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:50 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · nonDerivative · entry 1 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:53 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
GrantStock Option (Right to Buy) · Derivative | 5,732 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001880 · doc4.xml · derivative · entry 8 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,732 Underlying: Common Stock · 5,732 shares Expires 2035-02-13 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:53 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
GrantRestricted Stock Units · Derivative | 5,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001880 · doc4.xml · derivative · entry 7 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,652 Underlying: Common Stock · 5,652 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
Sorenson John BradleyEVP, Global Operations
|
GrantStock Option (Right to Buy) · Derivative | 10,909 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001878 · doc4.xml · derivative · entry 9 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,909 Underlying: Common Stock · 10,909 shares Expires 2035-02-13 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
Sorenson John BradleyEVP, Global Operations
|
GrantRestricted Stock Units · Derivative | 4,239 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001878 · doc4.xml · derivative · entry 8 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,239 Underlying: Common Stock · 4,239 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
GrantRestricted Stock Units · Derivative | 188 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · derivative · entry 18 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 188 Underlying: Common Stock · 188 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
GrantStock Option (Right to Buy) · Derivative | 6,061 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · derivative · entry 14 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,061 Underlying: Common Stock · 6,061 shares Expires 2035-02-13 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
GrantRestricted Stock Units · Derivative | 2,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001876 · doc4.xml · derivative · entry 13 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,355 Underlying: Common Stock · 2,355 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantStock Option (Right to Buy) · Derivative | 13,334 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001874 · doc4.xml · derivative · entry 8 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,334 Underlying: Common Stock · 13,334 shares Expires 2035-02-13 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
GrantRestricted Stock Units · Derivative | 5,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001874 · doc4.xml · derivative · entry 7 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,181 Underlying: Common Stock · 5,181 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 90,915 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · derivative · entry 9 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,915 Underlying: Common Stock · 90,915 shares Expires 2035-02-13 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
GrantRestricted Stock Units · Derivative | 35,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001871 · doc4.xml · derivative · entry 8 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,330 Underlying: Common Stock · 35,330 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
GrantStock Option (Right to Buy) · Derivative | 28,789 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · derivative · entry 9 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,789 Underlying: Common Stock · 28,789 shares Expires 2035-02-13 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC |
Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology
|
GrantRestricted Stock Units · Derivative | 11,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · derivative · entry 8 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,188 Underlying: Common Stock · 11,188 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
GrantStock Option (Right to Buy) · Derivative | 23,031 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001866 · doc4.xml · derivative · entry 9 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,031 Underlying: Common Stock · 23,031 shares Expires 2035-02-13 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC |
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC
|
GrantRestricted Stock Units · Derivative | 8,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001866 · doc4.xml · derivative · entry 8 Butcher Arthur C · CIK 0001678249 · EVP& Grp Pres, MedSurg & APAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,950 Underlying: Common Stock · 8,950 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
GrantStock Option (Right to Buy) · Derivative | 11,515 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · derivative · entry 8 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,515 Underlying: Common Stock · 11,515 shares Expires 2035-02-13 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
GrantRestricted Stock Units · Derivative | 4,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001864 · doc4.xml · derivative · entry 7 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,475 Underlying: Common Stock · 4,475 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC |
Brennan Daniel J.EVP and CFO
|
GrantStock Option (Right to Buy) · Derivative | 23,031 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,031 Underlying: Common Stock · 23,031 shares Expires 2035-02-13 F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:50 UTC |
Brennan Daniel J.EVP and CFO
|
GrantRestricted Stock Units · Derivative | 8,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001863 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,950 Underlying: Common Stock · 8,950 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 21:32 UTC |
Sorenson John BradleyEVP, Global Operations
|
SaleCommon Stock | 6,389 | $105.06 | $671,249.42 |
DisclosureSEC source: 0001225208-25-001686 · doc4.xml · nonDerivative · entry 4 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,293 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.81 to $105.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 21:32 UTC |
Sorenson John BradleyEVP, Global Operations
|
GiftCommon Stock | 2,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001686 · doc4.xml · nonDerivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,682 Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 21:32 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
SaleCommon Stock | 13,022 | $105.06 | $1,368,073.09 |
DisclosureSEC source: 0001225208-25-001685 · doc4.xml · nonDerivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,454 F2 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 28, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.787 to $105.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 21:31 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,087 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-25-001679 · doc4.xml · derivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,087 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 21:31 UTC |
Brennan Daniel J.EVP and CFO
|
SaleCommon Stock | 15,087 | $105.07 | $1,585,135.27 |
DisclosureSEC source: 0001225208-25-001679 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,451 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.778 to $105.28, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 21:31 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 15,087 | $16.31 | $246,068.97 |
DisclosureSEC source: 0001225208-25-001679 · doc4.xml · nonDerivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 256,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 26, 2024. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionRestricted Stock Units · Derivative | 480 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001796 · doc4.xml · derivative · entry 3 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,443 Underlying: Common Stock · 480 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 231 | $105.77 | $24,432.87 |
DisclosureSEC source: 0001225208-25-001796 · doc4.xml · nonDerivative · entry 2 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,206 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
Woodworth EmilySVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 480 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001796 · doc4.xml · nonDerivative · entry 1 Woodworth Emily · CIK 0002013518 · SVP, Global Controller and CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionRestricted Stock Units · Derivative | 1,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001795 · doc4.xml · derivative · entry 3 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,193 Underlying: Common Stock · 1,731 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
Sorenson John BradleyEVP, Global Operations
|
Tax withholdingCommon Stock | 530 | $105.77 | $56,058.10 |
DisclosureSEC source: 0001225208-25-001795 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,494 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
Sorenson John BradleyEVP, Global Operations
|
Exercise / conversionCommon Stock | 1,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001795 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 65 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001794 · doc4.xml · derivative · entry 6 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 196 Underlying: Common Stock · 65 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 961 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001794 · doc4.xml · derivative · entry 5 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,885 Underlying: Common Stock · 961 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 23 | $105.77 | $2,432.71 |
DisclosureSEC source: 0001225208-25-001794 · doc4.xml · nonDerivative · entry 4 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,544 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 65 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001794 · doc4.xml · nonDerivative · entry 3 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Tax withholdingCommon Stock | 338 | $105.77 | $35,750.26 |
DisclosureSEC source: 0001225208-25-001794 · doc4.xml · nonDerivative · entry 2 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,579 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:30 UTC |
O'Sullivan MiriamSVP, Chief HR Officer
|
Exercise / conversionCommon Stock | 961 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001794 · doc4.xml · nonDerivative · entry 1 O'Sullivan Miriam · CIK 0002048285 · SVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionRestricted Stock Units · Derivative | 2,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001793 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,347 Underlying: Common Stock · 2,115 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 868 | $105.77 | $91,808.36 |
DisclosureSEC source: 0001225208-25-001793 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,701 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,115 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001793 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 13,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001792 · doc4.xml · derivative · entry 4 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,112 Underlying: Common Stock · 13,704 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.